Oleoylethanolamide
Oleoyl ethanolamide
Snapshot
| Indications | Contraindications |
|---|---|
Oleoylethanolamide (OEA) is an endogenous lipid derived from oleic acid that signals satiety and fat handling after a meal.1, 2 Supplementation is used for appetite and weight management in adults with overweight or obesity. It is also used for cardiometabolic markers and gut health, with exploratory work in fatigue and mood.
An exploratory trial in veterans with Gulf War illness found less fatigue and better mood but no change in cognition or pain8. In a 2023 pilot study of fasting in healthy adults, OEA rose during fasting and, with three other metabolites, mimicked fasting's effects on human macrophages and extended roundworm lifespan; no human trial has tested longevity. Three products listing OEA appear in the label database, all multi-ingredient capsules or powders; see Form comparison.
Per United States (US) product labels, one of three advises consulting a physician before use with antidepressants, blood pressure or diabetes medications, or heart, liver, kidney, thyroid, or psychiatric conditions10.
Last updated October 17, 2026. Read how we make monographs.
In the full monograph
42 sources, 31 studies
- When to useThe situations practitioners use it for, each with the reason and the study behind it.
- SafetyWho should avoid it, who needs extra care, and the side effects reported in studies.
- InteractionsThe medicines and supplements it interacts with, the effect of each, and what labeling says to watch.
- Protocol notesThe doses used in studies, how and when they were taken, and how the forms on the market compare.
- How it worksWhat it is and how it works in the body, in plain terms.
- Published studiesThe studies behind each use, popular claims checked against them, and trials still under way.
- Word of mouthWhat patients and practitioners report online, kept separate from the clinical evidence.
- Clinical perspectiveA closing read of where the evidence is solid, where it is thin, and what has not been studied.
Sources
- 1A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity.pubmed.ncbi.nlm.nih.govTutunchi, Saghafi-Asl, Ostadrahimi · Clinical and experimental pharmacology & physiology · 2020 · Pubmed
- 2Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial.pubmed.ncbi.nlm.nih.govPayahoo, Khajebishak, Alivand et al. · Appetite · 2019 · Pubmed
- 3The effect of oleoylethanolamide supplementation on cardiometabolic factors: a systematic review and meta-analysis.pubmed.ncbi.nlm.nih.govEslahi, Rohani, Fatahi et al. · Cardiovascular endocrinology & metabolism · 2025 · Pubmed
- 4Oleoylethanolamide supplementation enriches Akkermansia muciniphila and modulates intestinal barrier function in adults with obesity: A randomized, double-blind, placebo-controlled trial.pubmed.ncbi.nlm.nih.govBatacan, Rao, Bajagai et al. · Gut microbes reports · 2026 · Pubmed
- 5Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study.pubmed.ncbi.nlm.nih.govBriskey, Pellow, Viswanath et al. · Frontiers in endocrinology · 2026 · Pubmed
- 6Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.pubmed.ncbi.nlm.nih.govTutunchi, Ostadrahimi, Saghafi-Asl et al. · Pharmacological research · 2020 · Pubmed
- 7Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: A randomized controlled trial.pubmed.ncbi.nlm.nih.govTutunchi, Zolrahim, Nikbaf-Shandiz et al. · Frontiers in pharmacology · 2023 · Pubmed
- 8Oleoylethanolamide supplementation improves mood and reduces fatigue in veterans with GWI in a 15-week randomized, double-blind, placebo-controlled exploratory clinical trial.pubmed.ncbi.nlm.nih.govAbdullah, Keegan, Hoffmann et al. · Scientific reports · 2026 · Pubmed
- 9Efficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction-associated fatty liver disease (MAFLD): a Bayesian network meta-analysis.pubmed.ncbi.nlm.nih.govYang, He, Cai et al. · Frontiers in pharmacology · 2025 · Pubmed
- 10US product labelsdsld.od.nih.govWarnings printed on US dietary supplement labels with this ingredient, from the NIH Office of Dietary Supplements' Dietary Supplement Label Database (DSLD). Manufacturers' precautions, not evidence of harm